Osteoarthritis
Conditions
Interventions
control group:a 60-ml cocktail, intraoprative, periarticular injection without morphine ( morphine hydrochloride 0 mg, compound betamethasone injection 6 mg, ropivacaine hydrochloride 100 mg).
Group A:a 60-ml cocktail, intraoprative, periarticular injection with morphine ( morphine hydrochloride 2 mg, compound betamethasone injection 6 mg, ropivacaine hydrochloride 100 mg).
Group B:a 60-ml cocktail, intraoprative, periarticular injection with morphine ( morphine hydrochloride 4 mg, compound betamethasone injection 6 mg, ropivacaine hydrochloride 100 mg).
Group C:a 60-ml cocktail, intraoprative, periarticular injection with morphine ( morphine hydrochloride 6 mg, compound betamethasone injection 6 mg, ropivacaine hydrochloride 100 mg).
Group D:a 60-ml cocktail, intraoprative, periarticular injection with morphine ( morphine hydrochloride 8 mg, compound betamethasone injection 6 mg, ropivacaine hydrochloride 100 mg).
Group E:a 60-ml cocktail, intraoprative, periarticular injection with morphine( morphine hydrochloride 4 mg, compound betamethasone injection 10 mg, ropivacaine hydrochloride 100 mg).
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of severe knee osteoarthritis according to the 2013 American Orthopedic Society Guidelines for the Treatment of Knee Osteoarthritis; 2. Patients undergoing unilateral total knee arthroplasty; 3. Aged older than 18 and younger than 80 years; 4. Patients with unilateral TKA for the first time; 5. Preoperative blood biochemistry, coagulation function, color Doppler ultrasound of lower extremity blood vessels and other related examinations showed no significant abnormalities; 6. Patients voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Abnormal coagulation function, thrombocytopenia and co-infection; 2. Complicated with severe cardiovascular and cerebrovascular diseases, severe diabetes mellitus, peripheral neuropathy, bone tumors, etc.; 3. Patients with autoimmune diseases such as rheumatoid and systemic lupus erythematosus; 4. Patients who are unwilling or unable to sign their informed consent independently; 5. Intolerant patients; 6. Patients allergic to drugs used in our institute; 7. Patients with psychiatric disorders; 8. Patients who are participating in other clinical trials; 9. Researchers believe that other reasons are not suitable for patients in clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS score of knee pain;ROM;HSS functional score of knee joint; | — |
Countries
China
Contacts
Public ContactLi Cao
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed